Joint Study with Leading US Hospital to Assess Impact of FeelBetter’s Precision Population Health Platform on Polypharmacy Patient Management

Prospective Research to Evaluate Potential of FeelBetter’s AI-Powered Platform as a Tool to Aid in Improving Patient Outcomes, Reducing Healthcare Costs, and Optimizing Care Journeys

BOSTON & TEL AVIV, Israel–(BUSINESS WIRE)–FeelBetter, the leading provider of polypharmacy patient management technology and pioneer of Pharmaco-Clinical Intelligence, today announced a collaboration on a prospective research study with investigators at Brigham and Women’s Hospital in Boston. The research will assess the impact of FeelBetter’s AI-based Precision Population Health Platform on polypharmacy patient management.

Launched in February 2024, the joint study will prospectively follow patients who are receiving care at the hospital’s Phyllis Jen Center for Primary Care, evaluating FeelBetter’s potential as a tool in improving health outcomes and reducing healthcare utilization and costs. This new study follows the publication of retrospective research conducted by investigators at Brigham and Women’s Hospital in 2022, which demonstrated that FeelBetter’s Pharmaco-Clinical Intelligence accurately predicts which senior patients are at high risk of medication-related adverse events and recommends relevant and appropriate changes to their medication regimens.

“Many polypharmacy problems aren’t detected until patients end up in the ER and, in seniors with several chronic diseases and conditions, the simultaneous use of multiple medications ultimately contributes to 10-30% of hospitalizations,” said Lisa Rotenstein, MD MBA MSc, the principal investigator of the study. “Our previous study showed that its platform can be used to identify which patients are at the highest risk of polypharmacy-related adverse events. Based on retrospective data, we’re excited to prospectively examine how the platform can potentially be used to improve patient outcomes, healthcare utilization, and cost efficiencies.”

David Bates, MD, MSc, Professor of Medicine at Harvard Medical School and Brigham and Women’s Hospital, added: “Especially for providers like affordable care organizations who are assuming risk for patients, it’s exciting to see new technologies being integrated with EHRs and added to clinical workflows. Reducing admission rates and downstream costs associated with high-risk patients by implementing evidence-based suggestions around improving their medication regimens will be beneficial for both patients and care teams.”

Presented at the Society of General Internal Medicine (SGIM) 2023 Annual Meeting and the 2023 Annual Research Meeting (ARM) of AcademyHealth, the retrospective research study concluded that FeelBetter can be used to effectively risk stratify emergency department use and hospitalizations among patients with multiple chronic conditions and complex medication regimens. Study results also indicated that, when paired with a medication management intervention, FeelBetter’s technology could potentially reduce healthcare utilization and expenses, and aid in improving patient outcomes.

“FeelBetter is on a mission to personalize the way healthcare is delivered, developing purpose-built technology to help clinicians risk stratify polypharmacy patients and proactively prevent related deterioration with timely clinical interventions such as medication regimen changes,” said Yoram Hordan, FeelBetter’s CTO, COO, and Co-Founder. “We’re delighted to expand our research partnership with Brigham & Women’s Hospital with the rollout of the prospective pilot and to be growing the body of evidence in support of our Pharmaco-Clinical Intelligence’s capabilities in improving patient outcomes and driving value-based care.”

As part of the pilot, Feelbetter will integrate its platform with Epic’s EHR to enable automated workflows. The FeelBetter platform leverages Pharmaco-Clinical Intelligence, a new category of technology the Company has pioneered combining AI-based analyses and novel, evidence-based pharmacology and clinical capabilities. By identifying patients who are at high risk of near-term hospitalization related to polypharmacy issues, providing recommended changes to medication regimens and other needed clinical interventions, and comprehensively monitoring progress, the FeelBetter platform is changing the paradigm in polypharmacy patient management at both the individual and population health levels.

About FeelBetter

FeelBetter is the pioneer of Pharmaco-Clinical Intelligence, changing the polypharmacy paradigm on both an individual and population health level with a comprehensive solution designed to tackle the challenges associated with suboptimal medication management. Powered by AI and machine learning capabilities, FeelBetter’s Pharmaco-Clinical Intelligence drives personalized medication management, helping healthcare professionals ensure that their patients’ medication regimens are safe, effective, and appropriate. The technology pinpoints patients at high risk of deterioration and preventable hospitalization due to suboptimal medication management, and proactively suggests immediate and actionable interventions to reduce these risks. Provider organizations use FeelBetter to monitor their patients’ progress and more proactively deliver the right follow-up care, as well as to efficiently allocate resources and minimize preventable, costly use of healthcare services.

Led by an interdisciplinary team of clinicians, clinical pharmacists, and technologists, FeelBetter is headquartered in Boston and Tel Aviv. Investors include Firstime Ventures, Shoni Health Ventures, Triventures, ARC, the innovation hub of Sheba Medical Center, Random Forest VC, The Group Ventures, and GoodCompany Ventures. To learn more, visit feelbetter.healthcare.

Contacts

FeelBetter:

Nicole Pariser

nicole@i-feelbetter.com

Press:

Bruno Solari

feelbetter@solcomms.co